Parabilis Medicines, Inc.(PBLS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
PBLS Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Parabilis Medicines, Inc. (PBLS), a Healthcare sector company. PBLS is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Parabilis Medicines, Inc. reports quarterly revenue of $148.0K, net income of $-52.5M. Top institutional holders of PBLS by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., FMR, ARCH Venture Management, based on the most recent SEC filings. PBLS trades on the Nasdaq exchange and files with the SEC under CIK 1657677. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PBLS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Parabilis Medicines, Inc. directly from SEC EDGAR.
Revenue
Q2 2026
$148.0K
Net Income
Q2 2026
$-52.5M
ROIC
Q2 2026
-19.1%
D/E Ratio
Q2 2026
0.02
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProTotal Assets
Total Debt
| Metric | FY 2025 | FY 2024 |
|---|---|---|
| Total Assets | $80.8M | — |
| Total Debt | $39.9M | — |
Get alerted when PBLS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Parabilis Medicines, Inc. including:
Top Institutional Holders of PBLS
RA CAPITAL MANAGEMENT, L.P.
$791.9M28,933,371 shFMR LLC
$281.7M10,292,735 shARCH Venture Management, LLC
$175.5M6,412,780 shvenBio Partners LLC
$144.1M5,266,697 shAlphabet Inc.
$134.6M4,919,498 shNextech Invest, Ltd.
$127.6M4,663,176 shCormorant Asset Management, LP
$126.3M4,615,612 shREGENERON PHARMACEUTICALS, INC.
$114.0M4,166,666 shSiren, L.L.C.
$81.9M2,992,259 shFARALLON CAPITAL MANAGEMENT LLC
$64.8M2,368,200 sh
| Fund | Value | Shares |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $791.9M | 28,933,371 |
| FMR LLC | $281.7M | 10,292,735 |
| ARCH Venture Management, LLC | $175.5M | 6,412,780 |
| venBio Partners LLC | $144.1M | 5,266,697 |
| Alphabet Inc. | $134.6M | 4,919,498 |
| Nextech Invest, Ltd. | $127.6M | 4,663,176 |
| Cormorant Asset Management, LP | $126.3M | 4,615,612 |
| REGENERON PHARMACEUTICALS, INC. | $114.0M | 4,166,666 |
| Siren, L.L.C. | $81.9M | 2,992,259 |
| FARALLON CAPITAL MANAGEMENT LLC | $64.8M | 2,368,200 |
More Healthcare Companies
View all Healthcare →Put PBLS on your watchlist
Track score changes the day Parabilis Medicines, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PBLS a good stock to buy?
13F Pro's AI-powered analysis of Parabilis Medicines, Inc. (PBLS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PBLS are available on the PBLS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PBLS is classified as a mid company.
Which hedge funds own PBLS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PBLS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Parabilis Medicines, Inc.'s investment landscape.